ICVX

Icosavax, Inc. [ICVX] Stock Forecast

Q: What is Icosavax, Inc. stock symbol ?

Icosavax, Inc. is a US stock, located in Seattle of Wa and trading under the symbol ICVX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

ICVX Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

ICVX has more than 27 years of cash runway (326 months)

Currently unprofitable, and not expected to turn profitable in the coming year

Top ICVX Correlated Resources

ICVX

Top 10 Correlated ETFs

ICVX

Top 10 Correlated Stocks

ICVX

In the News

11:16 10 Dec 2023 ICVX

Wall Street Analysts Believe Icosavax, Inc. (ICVX) Could Rally 175.87%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 175.9% in Icosavax, Inc. (ICVX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

10:34 10 Dec 2023 ICVX

Icosavax, Inc. (ICVX) is on the Move, Here's Why the Trend Could be Sustainable

Icosavax, Inc. (ICVX) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

08:00 10 Dec 2023 ICVX

Icosavax to Participate in the Cantor Fitzgerald Global Healthcare Conference 2023

SEATTLE, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today announced that the company will participate in the Cantor Fitzgerald Global Healthcare Conference 2023, taking place from September 26-28, 2023 in New York City.

12:43 10 Dec 2023 ICVX

Icosavax (ICVX) Up on Positive VLP Vaccine Candidate Data

Icosavax (ICVX) surges on positive data from the clinical study of IVX-A12, targeting respiratory syncytial virus and human metapneumovirus in older adults.

12:17 10 Dec 2023 ICVX

Why Shares of Icosavax Jumped on Tuesday

Icosavax also initiated a $67.8 million stock sale. The biopharmaceutical company's pipeline also includes vaccines to treat influenza and severe acute respiratory syndrome coronavirus.

12:11 10 Dec 2023 ICVX

Should You Buy Icosavax (ICVX) Ahead of Earnings?

Icosavax (ICVX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

06:59 10 Dec 2023 ICVX

Icosavax, Inc. (ICVX) Reports Q1 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) came out with a quarterly loss of $0.60 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.60 per share a year ago.

09:46 10 Dec 2023 ICVX

3 Biotech Stocks to Watch for Potential Breakthroughs

Biotech stock fortunes hinge upon potential, progress, and the ultimate realization of drugs and devices that treat diseases. Stringent regulatory processes and long development times result in substantial costs.

08:18 10 Dec 2023 ICVX

Icosavax (ICVX) Up 112% on Upbeat Data From RSV Jab Study

Data from an early-stage study showed that Icosavax's (ICVX) investigational RSV vaccine exhibited sustained immunologic response following six months of dose administration.

09:03 10 Dec 2023 ICVX

Icosavax, Inc. (ICVX) Reports Q3 Loss, Lags Revenue Estimates

Icosavax, Inc. (ICVX) delivered earnings and revenue surprises of 3.51% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ICVX Financial details

Company Rating

Neutral

Market Cap

526.45M

Income

-92.62M

Revenue

Book val./share

4.64

Cash/share

4.58

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

04 Apr 2024

P/E

-5.68

Forward P/E

-5.42

PEG

1.29

P/S

P/B

2.26

P/C

2.29

P/FCF

-7.14

Quick Ratio

17.59

Current Ratio

18.06

Debt / Equity

0.03

LT Debt / Equity

0.03

EPS (TTM)

-2.12

EPS next Y

-1.94

EPS next Q

-0.58

EPS this Y

-41.01%

EPS next Y

-8.3%

EPS next 5Y

12.26%

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

-25.42%

SMA20

51.9%

SMA50

28.11%

SMA100

9.25%

Inst Own

59.27%

Inst Trans

0.57%

ROA

-37%

ROE

-41%

ROC

-0.44%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

50.09M

Shs Float

32.5M

Target Price

52W Range

3.505-16.45

52W High

-34.31%

52W Low

+250.33%

RSI

60.1

Rel Volume

1.43

Avg Volume

316K

Volume

452.88K

Perf Week

2.74%

Perf Month

71.73%

Perf Quarter

7.46%

Perf Half Y

Beta

1.064

Volatility

0.34%, 1.85%

Prev Close

4.79%

Price

10.51

Change

2.04%

ICVX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0
Net income per share	-0.51	-6.67	-3.78	-2.23
Operating cash flow per share	-0.45	-4.94	-2.15	-1.55
Free cash flow per share	-0.45	-4.94	-2.2	-1.83
Cash per share	2.25	4.56	15.53	5.5
Book value per share	-0.8	-9.28	15.49	5.49
Tangible book value per share	-0.8	-9.28	15.49	5.49
Share holders equity per share	-0.8	-9.28	15.49	5.49
Interest debt per share	0	1.83	0.01	0.14
Market cap	358.11M	100.65M	411.06M	315.42M
Enterprise value	335.03M	92.48M	131.98M	265.37M
P/E ratio	-68.92	-5.25	-6.05	-3.57
Price to sales ratio	0	0	0	0
POCF ratio	-78.38	-7.08	-10.67	-5.11
PFCF ratio	-78.38	-7.08	-10.39	-4.33
P/B Ratio	-43.44	-3.77	1.48	1.45
PTB ratio	-43.44	-3.77	1.48	1.45
EV to sales	0	0	0	0
Enterprise value over EBITDA	-62.07	-4.94	-2.03	-2.79
EV to operating cash flow	-73.33	-6.51	-3.42	-4.3
EV to free cash flow	-73.33	-6.5	-3.34	-3.65
Earnings yield	-0.01	-0.19	-0.17	-0.28
Free cash flow yield	-0.01	-0.14	-0.1	-0.23
Debt to equity	0	-0.19	0	0.04
Debt to assets	0	0.31	0	0.04
Net debt to EBITDA	4.28	0.44	4.3	0.53
Current ratio	19.04	2.77	31.02	16.24
Interest coverage	0	-56.53	-436.17	28.81
Income quality	0.86	0.75	0.58	0.67
Dividend Yield	0	0	0	0
Payout ratio	0	0	0	0
Sales general and administrative to revenue	0	0	0	0
Research and developement to revenue	0	0	0	0
Intangibles to total assets	0	0	0	0
Capex to operating cash flow	0	0	0.03	0.18
Capex to revenue	0	0	0	0
Capex to depreciation	0	-11	-12.27	-12.92
Stock based compensation to revenue	0	0	0	0
Graham number	3.03	37.3	36.32	16.59
ROIC	0.64	0.88	-0.24	-0.39
Return on tangible assets	-0.22	-1.19	-0.24	-0.37
Graham Net	-0.83	-10.34	15.01	4.98
Working capital	22.07M	10.33M	277.32M	210.13M
Tangible asset value	-8.24M	-26.7M	278.22M	218.16M
Net current asset value	-8.24M	-26.71M	277.14M	203.4M
Invested capital	0	-0.19	0	0.04
Average receivables	0	0	0	0
Average payables	0	1.36M	2.91M	3.4M
Average inventory	0	0	0	0
Days sales outstanding	0	0	0	0
Days payables outstanding	0	0	0	0
Days of inventory on hand	0	0	0	0
Receivables turnover	0	0	0	0
Payables turnover	0	0	0	0
Inventory turnover	0	0	0	0
ROE	0.63	0.72	-0.24	-0.41
Capex per share	0	0	-0.06	-0.28

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0	0	0	0
Net income per share	-0.52	-0.54	-0.55	-0.59	-0.44
Operating cash flow per share	-0.44	-0.23	-0.52	-0.43	-0.38
Free cash flow per share	-0.54	-0.29	-0.56	-0.44	-0.38
Cash per share	5.57	5.48	4.76	5.52	4.58
Book value per share	5.68	5.48	4.85	5.53	4.64
Tangible book value per share	5.68	5.48	4.85	5.53	4.64
Share holders equity per share	5.68	5.48	4.85	5.53	4.64
Interest debt per share	0.2	0.17	0.2	0.19	0.16
Market cap	125.61M	316.1M	239.33M	444.57M	387.74M
Enterprise value	67.78M	266.05M	198.79M	297.94M	332.57M
P/E ratio	-1.51	-3.68	-2.65	-4.19	-4.4
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.23	-35.11	-11.06	-23.13	-20.44
PFCF ratio	-5.89	-27.36	-10.31	-22.34	-20.4
P/B Ratio	0.56	1.45	1.2	1.79	1.67
PTB ratio	0.56	1.45	1.2	1.79	1.67
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-2.95	-10.59	-7.5	-10.29	-13.16
EV to operating cash flow	-3.9	-29.55	-9.18	-15.5	-17.53
EV to free cash flow	-3.18	-23.03	-8.56	-14.97	-17.5
Earnings yield	-0.17	-0.07	-0.09	-0.06	-0.06
Free cash flow yield	-0.17	-0.04	-0.1	-0.04	-0.05
Debt to equity	0.03	0.04	0.04	0.03	0.03
Debt to assets	0.03	0.04	0.04	0.03	0.03
Net debt to EBITDA	2.51	1.99	1.53	5.06	2.18
Current ratio	17.55	16.24	15.67	16.76	18.06
Interest coverage	-19.83	11.78	41.25	0	0
Income quality	0.79	0.38	0.88	0.73	0.86
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.23	0.28	0.07	0.04	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-27.66	-4.12	-2.45	-1.02	-0.04
Stock based compensation to revenue	0	0	0	0	0
Graham number	8.18	8.16	7.73	8.58	6.79
ROIC	-0.09	-0.1	-0.11	-0.11	-0.1
Return on tangible assets	-0.09	-0.09	-0.11	-0.1	-0.09
Graham Net	5.11	4.97	4.56	5.04	4.2
Working capital	215.7M	210.13M	189.27M	236.69M	222.28M
Tangible asset value	225.66M	218.16M	200.08M	247.72M	232.38M
Net current asset value	210.52M	203.4M	193.58M	230.4M	216.39M
Invested capital	0.03	0.04	0.04	0.03	0.03
Average receivables	0	0	0	0	0
Average payables	4.1M	3.81M	2.25M	1.58M	1.39M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.09	-0.1	-0.11	-0.11	-0.09
Capex per share	-0.1	-0.06	-0.04	-0.02	0

ICVX Frequently Asked Questions

What is Icosavax, Inc. stock symbol ?

Icosavax, Inc. is a US stock , located in Seattle of Wa and trading under the symbol ICVX

Is Icosavax, Inc. buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $27. The lowest prediction is $27 and the highest is $27

What is ICVX stock prediction ?

What is Icosavax, Inc. stock quote today ?

Icosavax, Inc. stock price is $10.51 today.

Is Icosavax, Inc. stock public?

Yes, Icosavax, Inc. is a publicly traded company.

Something similar

Top by Market Cap

LLY.DE

BRK-A

MSF.DE

Company Profile

Volume Average 316K
Market Capitalization 526.45M
Employee 60
CEO Mr. Adam K. Simpson
Headquarters Seattle,WA,US
IPO Date 2021-07-29
Website https://icosavax.com

Icosavax, Inc., a biopharmaceutical company, develops vaccines against infectious diseases. The company, with the help of its virus-like particle (VLP) platform technology, focuses primarily on life-threatening respiratory diseases. Its products in pipeline include IVX-121, a vaccine candidate with RSV target and is under Phase 1/1b clinical trial; IVX-A12, a respiratory syncytial virus (RSV) monovalent antigen candidate with RSV/human metapneumovirus (hMPV) bivalent target indication; IVX-241, a vaccine candidate with hMPV target; and IVX-411, an original receptor binding domain (RBD) sequence antigen with SARS-CoV-2 target indication and is under Phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in Seattle, Washington.